Royalty Pharma plc cash flow statement

In fiscal 2025, Royalty Pharma plc's operations generated $2.49bn of cash. It returned $1.23bn through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Royalty Pharma plc: cash flow statement, annual
Fiscal year	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Cash from operations	1,618	1,667	2,035	2,018	2,144	2,988	2,769	2,490	2,976
Depreciation and amortisation	—	—	—	—	—	0	0	4	5
Stock-based pay	0	0	5	2	2	2	2	290	428
Share buybacks	0	4	0	0	0	305	230	1,227	322

US$ millions unless shown otherwise. Fiscal quarters.

Royalty Pharma plc: cash flow statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Cash from operations	704	743	596	364	703	827	718	728
Depreciation and amortisation	0	0	0	1	1	1	1	1
Stock-based pay	1	1	1	91	73	126	122	107

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: AMRX vs RPRX LNTH vs RPRX PAHC vs RPRX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Royalty Pharma plc's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Royalty Pharma plc.